CD19 CAR-T细胞治疗大B细胞淋巴瘤前游离DNA低深度全基因组测序风险评估
研究对122例接受标准CD19 CAR-T治疗的复发难治大B细胞淋巴瘤患者,在白细胞采集时进行血浆游离DNA低深度全基因组测序,定义DNA拷贝数改变。高局灶性拷贝数改变评分与较差的3个月完全缓解率、无进展生存和总生存相关,结合传统肿瘤负荷标志物构建的风险模型可可靠分层。
要点
- 高局灶性拷贝数改变评分是治疗前与3个月完全缓解率、无进展生存和总生存相关的最显著变量。
- 10q23.3缺失导致FAS死亡受体丢失与较差的无进展生存和总生存高度相关。
- 结合局灶性拷贝数改变评分、乳酸脱氢酶升高和>1个结外位点构建的风险模型可可靠进行风险分层。
核心结论
- 游离DNA低深度全基因组测序是一种微创检测方法,可快速识别高危患者,并可能指导患者选择和未来临床试验中评估的靶向治疗。
研究设计与样本
- 对122例接受标准CD19 CAR-T治疗的复发难治大B细胞淋巴瘤患者,在白细胞采集时采集治疗前血浆样本进行低深度全基因组测序。
主要发现
- 高局灶性拷贝数改变评分与较低的3个月完全缓解率相关(28% vs 56%,P = .0029)。
- 高局灶性拷贝数改变评分与较差的无进展生存相关(P = .0007;风险比2.11)和总生存相关(P = .0026;风险比2.10)。
- 在108例(89%)患者中识别出34种独特的局灶性拷贝数改变,其中10q23.3缺失导致FAS死亡受体丢失与较差的无进展生存相关(P < .0001;风险比3.49)和总生存相关(P = .0027;风险比2.68)。
- 结合局灶性拷贝数改变评分与乳酸脱氢酶升高和>1个结外位点构建的风险模型可可靠进行风险分层。
关键数值与推荐
- 高局灶性拷贝数改变评分组3个月完全缓解率为28%,低评分组为56%(P = .0029)。
- 高局灶性拷贝数改变评分组无进展生存风险比为2.11(P = .0007),总生存风险比为2.10(P = .0026)。
- 10q23.3缺失组无进展生存风险比为3.49(P < .0001),总生存风险比为2.68(P = .0027)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with relapsed or refractory large B-cell lymphomas (rrLBCL) can achieve long-term remission after CD19 chimeric antigen receptor T-cell therapy (CART19). However, more than half of recipients will experience treatment failure. Thus, approaches are needed to identify high-risk patients who may benefit from alternative or consolidative therapy. We evaluated low-pass whole-genome sequencing (lpWGS) of cell-free DNA (cfDNA) before CART19 as a new approach for risk stratification. We performed lpWGS on pretreatment plasma samples from 122 patients at time of leukapheresis who received standard-of-care CART19 for rrLBCL to define DNA copy number alterations (CNAs). In multivariable selection, high focal CNA score (FCS) denoting genomic instability was the most significant pretreatment variable associated with inferior 3-month complete response rates (28% vs 56%, P = .0029), progression-free survival (PFS; P = .0007; hazard ratio, 2.11), and overall survival (OS; P = .0026; hazard ratio, 2.10). We identified 34 unique focal CNAs in 108 (89%) patients; of these, deletion 10q23.3 leading to loss of FAS death receptor was the most highly associated with poor outcomes, leading to inferior PFS (P < .0001; hazard ratio, 3.49) and OS (P = .0027; hazard ratio, 2.68). By combining FCS with traditional markers of increased tumor bulk (elevated lactate dehydrogenase and >1 extranodal site), we built a simple risk model that could reliably risk stratify patients. Thus, lpWGS of cfDNA is a minimally invasive assay that could rapidly identify high-risk patients and may guide patient selection for and targeted therapies to evaluate in future clinical trials.
引用
- Cherng HJ, Sun R, Sugg B, et al. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood. 2022. PMID: 35512184. doi:10.1182/blood.2022015601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。